Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'Just right' or plain wrong?

Current Opinion in Chemical Biology

Volumn 6, Issue 4, 2002, Pages 510-525

  Carter, Percy H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RECEPTOR BLOCKING AGENT; SB 265610; SCH 350634; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG INDUSTRY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE; TH2 CELL;

MURINAE;

EID: 0036679740     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(02)00351-4     Document Type: Review

References (175)

1. Chemokines: Immunology's high impact factors
2. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
3. Involvement of chemokine receptors in breast cancer metastasis
4. Chemokines: Agents for the immunotherapy of cancer?
5. Chemokines: A new classification system and their role in immunity
6. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection
7. CXC chemokine receptor 2 but not C-C chemokine receptor 1 expression is essential for neutrophil recruitment to the cornea in helminth-mediated keratitis (river blindness)
8. CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses
9. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats
10. Interleukin-8 receptor (CXCR2) antagonists
11. CXCR2 is necessary for the development and persistence of chronic fungal asthma in mice
12. Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/interleukin-8RB
13. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: Role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis
14. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium
15. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor
16. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
17. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2
18. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2
19. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
20. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome
21. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice
22. Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages
23. Leukocyte recruitment during the onset of experimental allergic encephalomyelitis is CCR1 dependent
24. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
25. Identification and characterization of potent, selective, and orally active antagonist of the CC chemokine receptor-1
26. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection
27. CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model
28. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation
29. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1.alpha. or its CCR5 receptor
30. CCR5 Delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis
31. Delta 32 deletion of CCR5 gene and association with asthma or atopy
32. Delta32 mutation of the chemokine-receptor 5 gene in inflammatory bowel disease
33. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis
34. Unique role of the chemokine domain of fractalkine in cell capture: Kinetics of receptor dissociation correlate with cell adhesion
35. Tumor necrosis factor-α-converting enzyme mediates the inducible cleavage of fractalkine
36. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection
37. Generation and analysis of mice lacking the chemokine fractalkine
38. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion
39. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection
40. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease
41. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis
42. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness
43. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation
44. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation
45. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo
46. A role for the C3a anaphylatoxin receptor in the effector phase of asthma
47. Critical involvement of the chemotactic axis CXCR4/stromal-derived factor-1α in the inflammatory component of allergic airway disease
48. Variant eotaxin: Its effects on the asthma phenotype
49. Rules of chemokine receptor association with T cell polarization in vivo
50. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics
51. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection
52. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection
53. Requirement of the chemokine receptor CXCR3 for acute allograft rejection
54. CXCL10 (IFN-γ-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis
55. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis
56. Multiple sclerosis: A study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system
57. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo
58. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
59. Role of C chemokine lymphotactin in mediating recruitment of antigen-specific CD62Lo cells in vitro and in vivo
60. Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation
61. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses
62. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis
63. The role of cc chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice
64. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: Lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine
65. Protection from pulmonary fibrosis in the absence of CCR2 signaling
66. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
67. Safe use of the CXCR4 inhibitor ALX40-4C in humans
68. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice
69. Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4
70. Persistent induction of the chemokine receptor CXCR4 by TGF-β1 on synovial T cells contributes to their accumulation within the rheumatoid synovium
71. Increased CCR4 expression in active systemic lupus erythematosus
72. CC chemokine receptor 4 expression on peripheral blood CD4+ T cells reflects disease activity of atopic dermatitis
73. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation
74. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice
75. A key role for the CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock
76. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice
77. Chemokines and the tissue-specific migration of lymphocytes
78. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation
79. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin
80. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease
81. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects
82. Macrophage inflammatory protein 3.alpha. is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting langerhans cell precursors
83. Up-regulation of macrophage inflammatory protein-3.alpha./CCL20 and CC chemokine receptor 6 in psoriasis
84. NMR solution structure of murine CCL20/MIP-3α, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the β
85. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses
86. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue
87. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation
88. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines
89. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position
90. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells
91. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
92. Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection
93. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis
94. Lack of CCR2 results in increased mortality and impaired leukocyte activation and trafficking following infection of the central nervous system with a neurotropic coronavirus
95. A mechanism for the impaired IFN-γ production in C-C chemokine receptor 2 (CCR2) knockout mice: Role of CCR2 in linking the innate and adaptive immune responses
96. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans
97. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis
98. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice
99. Enhanced pulmonary allergic responses to Aspergillus in CCR2 -/- mice
100. Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2)
101. CC chemokine receptor-2 is not essential for the development of antigen-induced pulmonary eosinophilia and airway hyperresponsiveness
102. Antifungal and airway remodeling roles for murine monocyte chemoattractant protein-1/CCL2 during pulmonary exposure to Aspergillus fumigatus conidia
103. Chemokines as regulators of T cell differentiation
104. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3
105. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking the CC chemokine receptor 1
106. Airway remodeling is absent in CCR1 -/- mice during chronic fungal allergic airway disease
107. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity
108. Nicotinamide N-oxides as CXCR2 antagonists
109. Discovery of novel non-peptide CCR1 receptor antagonists
110. Design, synthesis, and discovery of a novel CCR1 antagonist
111. Discovery of a novel CCR3 selective antagonist
112. CCR3 antagonists: A potential new therapy for the treatment of asthma. Discovery and structure-activity relationships
113. Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2
114. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists
115. Discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection
116. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist
117. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5
118. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
119. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: A proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted) piperidin-1-yl]butanes
120. CCR5 antagonists: Bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines
121. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity
122. Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection
123. Monomeric solution structure of the prototypical 'C' chemokine lymphotactin
124. Structural comparison of monomeric variants of chemokine MIP-1β having differing ability to bind the receptor CCR5
125. Two-site binding of C5a by its receptor: An alternative binding paradigm for G protein-coupled receptors
126. Solution structure and basis for functional activity of stromal cell-derived factor-1; Dissociation of CXCR4 activation from binding and inhibition of HIV-1
127. Molecular determinants of receptor binding and signaling by the CX3C chemokine fractalkine
128. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties
129. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1
130. N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities
131. Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin
132. Mutagenesis studies of interleukin-8
133. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES
134. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand
135. Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies
136. The TXP motif in the second transmembrane helix of CCR5
137. Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3
138. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
139. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: Binding to a common chemokine receptor motif within the helical bundle
140. 2b receptor antagonists based on indole-2-carboxylic acid
141. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor
142. Structure and function of G protein-coupled receptors
143. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1α: Implications for development of selective CXCR4 antagonists
144. Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2
145. RANTES activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells
146. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors
147. Point mutation that confers constitutive activity to CXCR4 reveals T140 is an inverse agonist and AMD3100 and ALX40-4C are weak partial agonists
148. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis
149. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis
150. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat
151. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness
152. Viral exploitation and subversion of the immune system through chemokine mimicry
153. The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site
154. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC)
155. Uncoupling of inflammatory chemokine receptors by IL-10: Generation of functional decoys
156. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor
157. + gut intraepithelial lymphocytes
158. A role for CCR9 in T lymphocyte development and migration
159. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog
160. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development
161. Impaired B-lymphopoiesis, myelopoiesis and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice
162. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract
163. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen
164. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse
165. Mice lacking the murine interleukin-8 receptor homologue demonstrate paradoxical responses to acute and chronic experimental infection with Listeria monocytogenes
166. Beneficial effects of targeting CCR5 in allograft recipients
167. Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation
168. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2 -/- mice: The role of mast cells
169. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and TH1-like/CD45RO+ T cells
170. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways
171. Drug efficacy at G protein-coupled receptors
172. Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists
173. Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists
174. C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor